Le Lézard
Classified in: Business, Covid-19 virus
Subjects: EARNINGS, Conference, Webcast, Advisory

Kimball Electronics, Inc. Announces Date for Reporting First Quarter Fiscal 2022 Financial Results


Kimball Electronics, Inc. (Nasdaq: KE) today announced that it will report first quarter fiscal 2022 financial results on Wednesday, November 3, 2021 after the closing of the market. The company will host a conference call and live webcast to review the results on Thursday, November 4, 2021, at 10:00 a.m. Eastern Time.

The telephone number to access the conference call is 877-248-9893 in the United States, or 873-415-0287 for other locations. Please reference conference ID 8062466. A live webcast of the conference call can be accessed at https://investors.kimballelectronics.com. For those unable to participate in the live webcast, a replay will be archived at https://investors.kimballelectronics.com.

Annual Meeting of Share Owners

The company will hold its Annual Meeting of Share Owners on Tuesday, November 9, 2021 at 9:00 a.m. Eastern Time. The meeting is scheduled to take place at the Kimball Electronics, Inc. Headquarters at 1205 Kimball Blvd. in Jasper, Indiana. Registered Share Owners as of the September 10, 2021 record date are entitled to submit proxies or vote in person at the Annual Meeting of Share Owners. Appropriate COVID-19 safety protocols will be in place for the in-person annual meeting, which may include temperature taking, masking, and/or social distancing.

About Kimball Electronics, Inc.
Kimball Electronics is a multifaceted manufacturing solutions provider of electronics and diversified contract manufacturing services to customers around the world. From our operations in the United States, China, India, Japan, Mexico, Poland, Romania, Thailand, and Vietnam, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values personal and organizational commitment to quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (Nasdaq: KE) is headquartered in Jasper, Indiana.

To learn more about Kimball Electronics, visit: www.kimballelectronics.com.

Lasting relationships. Global success.


These press releases may also interest you

18 avr 2024
Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 - Exclusive Report by 360iResearch
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
SETC-Assistance.org Helps Eligible Self-Employed Workers Receive Up to $32,220 in Tax Credits Through SETC Program
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDEL
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

18 avr 2024
Bladex announces 1Q24 Net Profit of $51.3 Million, or $1.40 per share, expanding its annualized return on equity to 16.8% in 1Q24
Banco Latinoamericano de Comercio Exterior, S.A. , a Panama-based multinational bank originally established by the central banks of 23 Latin-American and Caribbean countries to promote foreign trade and economic integration in the Region, announced...

More news about Covid-19 virus...


News published on and distributed by: